Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Gross Margin (2023 - 2025)

Historic Gross Margin for Fennec Pharmaceuticals (FENC) over the last 3 years, with Q3 2025 value amounting to 58.19%.

  • Fennec Pharmaceuticals' Gross Margin rose 241700.0% to 58.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.58%, marking a year-over-year decrease of 116900.0%. This contributed to the annual value of 61.24% for FY2024, which is 328400.0% down from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Gross Margin of 58.19% as of Q3 2025, which was up 241700.0% from 54.89% recorded in Q2 2025.
  • Fennec Pharmaceuticals' Gross Margin's 5-year high stood at 95.55% during Q2 2023, with a 5-year trough of 34.03% in Q3 2024.
  • Over the past 3 years, Fennec Pharmaceuticals' median Gross Margin value was 66.32% (recorded in 2025), while the average stood at 68.78%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -608900bps in 2024, then soared by 241700bps in 2025.
  • Fennec Pharmaceuticals' Gross Margin (Quarter) stood at 92.96% in 2023, then crashed by -46bps to 50.23% in 2024, then rose by 16bps to 58.19% in 2025.
  • Its Gross Margin stands at 58.19% for Q3 2025, versus 54.89% for Q2 2025 and 66.32% for Q1 2025.